Van Meter Says Ivantis Making Moves in MIGS

Dave Van Meter, president and CEO of Ivantis, explains how the company’s Hydrus Microstent plans to grab a piece of the growing MIGS market. He also shares why he shifted from interventional cardiology to ophthalmology and what challenges he overcame in making that switch.